Johnson & Johnson $JNJ Stock Position Reduced by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 73.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,236 shares of the company’s stock after selling 6,065 shares during the period. Johnson & Johnson makes up about 1.0% of Thurston Springer Miller Herd & Titak Inc.’s portfolio, making the stock its 13th biggest holding. Thurston Springer Miller Herd & Titak Inc.’s holdings in Johnson & Johnson were worth $592,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JNJ. National Pension Service lifted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B increased its holdings in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after buying an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC increased its holdings in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after buying an additional 6,539 shares during the last quarter. Finally, Gradient Investments LLC raised its stake in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ stock traded up $4.55 on Wednesday, reaching $253.16. 4,213,989 shares of the company’s stock were exchanged, compared to its average volume of 7,974,220. The stock has a fifty day moving average of $265.89 and a 200-day moving average of $249.37. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The firm has a market cap of $610.09 billion, a PE ratio of 29.31, a P/E/G ratio of 2.70 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.09 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted EPS of $2.59, above the $2.53 consensus, while revenue increased 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth driver, with strong oncology performance, renewed immunology growth and rising demand for TREMFYA. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and adjusted EPS of $11.05-$11.15. The guidance increase supports the view that pharmaceutical momentum is offsetting near-term device-market pressure. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: The company maintained its shareholder-return appeal by declaring a $1.34 quarterly dividend, equivalent to $5.36 annually and roughly a 2.2% yield at the referenced price. Johnson & Johnson dividend announcement
• Neutral Sentiment: Johnson & Johnson is leaning toward spinning off its hips-and-knees orthopedic business, with a targeted completion around mid-2027. The move could sharpen the company’s portfolio, but investors are focused on execution and possible earnings dilution from the separation and recent drug deals. Johnson & Johnson MedTech orthopedics spinoff
• Negative Sentiment: MedTech growth was only about 2.5% operationally and missed expectations, particularly in cardiovascular and surgery businesses outside the United States. Middle East-related budget and market disruptions added pressure, raising concerns about the segment’s growth trajectory. Johnson & Johnson MedTech-focused earnings coverage
• Negative Sentiment: Reported third-quarter profit was heavily reduced by charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. GAAP EPS fell to approximately $0.09, overshadowing the adjusted earnings beat. Johnson & Johnson Q3 earnings call highlights
• Negative Sentiment: Royal Bank of Canada lowered its price target from $290 to $280, while Erste Group reduced its 2027 EPS estimate to $12.65 from $12.83. These revisions signal that analysts see less near-term upside despite retaining generally constructive ratings.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. Guggenheim reaffirmed a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, HSBC lifted their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $273.61.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.